About Us

The Company

Cavidi is Sweden’s leading supplier of viral load for HIV monitoring. Cavidi’s products enable efficient management of anti-HIV drugs (ARV therapy) so that people living with HIV can live a normal lifespan. Cavidi’s diagnostics reduce the cost of treatment and the spread of HIV. Cavidi also provides tools and kits for virus research to many of the world’s leading labs.

Cavidi is a Swedish biotech company founded as a spin-off from Uppsala University. Our expertise is based on understanding viruses and using this knowledge to create research tools and clinical diagnostics. Today our focus is on HIV but our methods and expertise can be applied to other viruses.

Cavidi’s head office is in Uppsala, Sweden and we have sales offices in South Africa, India and USA. Our customers include hospitals, patient clinics, private laboratories, the pharmaceutical industry and research institutions worldwide.

Cavidi is ISO13485 certified for quality management systems.

>> Download the Corporate Cavidi Brochure

Board of Directors

David Mandel, CEO Narhex Life Sciences Ltd, BSc, CMA, FTA, MAICD

After 20 years of increasingly senior Sales & Marketing, Treasury, Finance & Administration roles in a range of multinational companies in England, Australia and USA, he became the CEO of a $100 million Australian subsidiary of Riverwood International Inc. In the past decade he has worked as a consultant, primarily working with start-up companies, some of which were biotech companies. He is a presently a Director of Narhex Life Sciences Ltd and Cavidi AB. He has a BSc in Chemistry from the University of Sussex, and he is also a Chartered Management Accountant (CMA), a senior member of the Finance & Treasury Association of Australia (FTA), and a Member of the Australian Institute of Company Directors (MAICD).

Clas Källander, Founder, R&D Director

Clas co-founded Cavidi Tech AB in 1984. He remains with Cavidi AB today as a member of its board of directors, having previously served on Cavidi Tech AB’s board. Clas is an Associate Professor of Medical Virology at Uppsala University and has authored more than 60 research publications.

Matt Hantzmon, VP Business Development, Diffusion Pharmaceuticals

Senior level executive, with proven record of success in financial management, strategic planning, marketing, manufacturing and operations including international market development, business development, FDA compliant cGMP manufacturing and strategic planning to name a few. Founder of three biotechnology companies. MBA, Kellogg Graduate School of Management, Northwestern University. Certified Management Accountant (CMA).

John Reisky de Dubnic, CEO

John started with Cavidi in 2005 as a consultant to the CEO in global strategic planning. He joined the board in 2008 representing US investors. In 2009 he led a reorganization of Cavidi and was appointed CEO of the company. With over 25 years experience in sales and services management, John has held senior management positions in Boston, Prague, and London. He moved to Sweden in 2001 with Turbec AB (JV of Volvo/ABB) where he served as V.P. Global Sales and Marketing. He then joined Schneider Electric as Director of Corporate Marketing and Business Development for TAC AB. John is a certified Sales Coach. He holds a B.S. in civil engineering from the University of Virginia and an MBA from the Darden School of Business.

Bob Lee, Partner MAQS Law Firm

Bob is a seasoned lawyer and specializes in Banking and Finance, Capital Markets and Mergers and Acquisitions. His 20 years’ experience as a legal practitioner includes positions as Corp. Counsel for a real estate company, General Counsel for a publically traded IT-company, Senior Manager at Ernst & Young Law as well as positions with several high profile law firms.

Scientific Advisory Committee

Professor John Mills

Chairman Emeritus, Cavidi AB, SB MD FACP FRACP ARCPA, Association of American Scientists (AAAS), Fellow Infectious Disease Society of America, Member Australasian Society of HIV Medicine, Community service Chair, Research Committee, and Director, Prostate Cancer Foundation of Australia, also Managing Director, TissuPath Pty Ltd, Non-executive Director of GBS Venture Partners P/L and Non-executive Director of Phosphagenics Corp (ASX: POH).

Professor Suzanne Crowe

AM, Macfarlane Burnet Institute for Medical Research and Public Health: Head, Pathogenesis and Clinical Research Program Centre for Virology, Head of Flow Cytometry Laboratory, Head of Clinical Research Laboratory. Consultant Physician in Infectious Diseases and General Medicine, Alfred Hospital, Melbourne, Professor of Medicine and Infectious Diseases (Personal Chair), Monash University, Melbourne, NHMRC Principal Research Fellow, awarded Member of the Order of Australia (AM) for her service to medical research in HIV/AIDS medicine and infectious diseases.

Dr. Brendan Larder

Chair RDI Scientific Core Group. Dr Larder is one of the world's leading experts in the fields of HIV drug resistance and pharmacogenomics. He holds a PhD in Virology from Cambridge University. Dr. Larder discovered HIV drug resistance. His seminal work on AZT resistance and its genetic basis published in Science in 1989. Dr. Larder has continued to pioneer understanding in the field, unraveling the genetic basis of resistance to several other HIV drugs and developing many of the laboratory techniques for studying HIV drug resistance, including phenotyping and genotyping methodologies.

Professor Anders Sönnerborg

Adjunct professor in infectious disease Virology at the Department of Medicine, Karolinska University Hospital, Sweden. Anders focuses on research concerning mechanisms of resistance and failure to improve HIV-specific immunity in HIV treatment. In vitro experiments in model systems combined with experimental analysis of well-defined patient populations.

Associate Professor Johan Lennerstrand

Associate professor Section of Virology, Department of Medical Sciences, Uppsala University and University Hospital, Uppsala, Sweden.

Ex-officio members

Clas Källander

Founder and Director of R&D, CAVIDI AB

Ingvar Petersson

Scientific Affairs Manager, CAVIDI AB.

Cavidi FAQ

Does Cavidi focus exclusively on resource-limited nations?

No. Our goal is to create tests that are universally accessible to both developed and developing nations alike. Within that mandate, we must address the fact that three quarters of the world’s population live in resource-limited settings.

What do all Cavidi products have in common?

Many medical tests can only be run in highly advanced medical facilities. Cavidi’s vision is a world where proper medical tests are accessible to anyone who needs them. So we strive to produce state-of-the-art tests with a minimal resource footprint. This approach makes Cavidi tests globally applicable but particularly attractive in settings where resources are limited.

How will Cavidi make medical testing more accessible?

At Cavidi we try to develop test solutions that adhere to our ACCESS policy:
  • Affordable in the context of resource-limited settings
  • Clinically relevant to both the diseases and measurement parameters needed
  • Comparable to similar tests used in developed nations with regard to accuracy and reliability
  • Easy to run and read in the field
  • Swifter at showing results
  • Suited to the infrastructure-limitations of resource-limited settings